Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020
Last odonate therapeutics, inc earnings: 4/28 08:15 am
Check Earnings Report
US:NASDAQ Investor Relations: ir.odonate.com/contact-ir
NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2020.As of December 31, 2020, Odonate had $157.3 million in cash, compared to $180.5 million as of December 31, 2019. This decrease in cash resulted primarily from cash used in operating activities for the twelve months ended December 31, 2020 of $113.1 million, partially offset by the receipt of $87.4 million of net proceeds from Odonate’s September 2020 underwritten public offering. Odonate’s net loss for the three and twelve months ended December 31, 2020 was $32.3 million and $126.4 million, or $0.87 and $3.84 per share, respectively, compared to $27.9 million and $111.8 million, or $0.91 and $4.05 per share, respectively, for the same periods in 2019.“Positive results of CONTESSA, Odo
[Read more]
| Impact snapshot | Event time: | ODT | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ODT alerts
ODT alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ODT alerts
High impacting Odonate Therapeutics, Inc news events
Weekly update
A roundup of the hottest topics
ODT
News
- Tang Capital Partners reports 41.6% stake in Odonate Therapeutics [Seeking Alpha]Seeking Alpha
- Odonate Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/ODT/price-target/">NASDAQ: ODT</a>) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.MarketBeat
- Odonate Therapeutics reports positive late-stage CONTESSA data of Tesetaxel in patients with metastatic breast cancer [Seeking Alpha]Seeking Alpha
- Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)Business Wire
- Odonate Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/ODT/price-target/">NASDAQ: ODT</a>) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating.MarketBeat
- More
ODT
SEC Filings
- 3/2/21 - Form 4
- 3/2/21 - Form 4
- 2/23/21 - Form 8-K
- ODT's page on the SEC website
- More